mardepodect

Mardepodect is a selective, orally active small molecule inhibitor of phosphodiesterase 10A (PDE10A), developed by Pfizer primarily for the treatment of schizophrenia and Huntington's disease. PDE10A is an enzyme highly expressed in the brain, especially in regions such as the striatum, nucleus accumbens, and olfactory tubercle. By inhibiting PDE10A, mardepodect increases intracellular levels of cyclic nucleotides (cAMP and cGMP), which modulate signal transduction pathways involved in dopamine signaling. This mechanism is thought to regulate dopamine-sensitive medium spiny neurons—key targets for antipsychotic drugs—and may offer therapeutic benefits distinct from conventional dopamine or serotonin receptor antagonists. Mardepodect advanced to Phase II clinical trials but development was discontinued for both schizophrenia and Huntington's disease[1][5][6][7].

Brand names

mardepodect

Other names

mardepodect